消化器内科 論文(2019年)
英語論文
| 著者 | タイトル | ジャーナル |
| Hamauchi S, Furuse J, Takano T, Munemoto Y, Furuya K, Baba H, Takeuchi M, Choda Y, Higashiguchi T, Naito T, Muro K, Takayama K, Oyama S, Takiguchi T, Komura N, Tamura K. | A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. | Cancer. |
| Mitsuhiro Furuta, Tomoya Yokota, Takahiro Tsushima, Akiko Todaka, Nozomu Machida, Satoshi Hamauchi, Kentaro Yamazaki, Akira Fukutomi, Sadayuki Kawai, Takanori Kawabata, Yusuke Onozawa, Hirofumi Yasui | Comparison of enteral nutrition with total parenteral nutrition for patients with locally advanced unresectable esophageal cancer harboring dysphagia in definitive chemoradiotherapy. | Jpn J Clin Oncol. |
| Shirasu H, Todaka A, Omae K, Fujii H, Mizuno N, Ozaka M, Ueno H, Kobayashi S, Uesugi K, Kobayashi N, Hayashi H, Sudo K, Okano N, Horita Y, Kamei K, Yukisawa S, Kobayashi M, Fukutomi A. | Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. | Cancer Sci. |
| Hayashi K,Mitani S,Taniguchi H,Yasui H,Muro K,Mori K,Gotoda T,Yamazaki K. | Panitumumab Provides Better Survival Outcomes Compared to Cetuximab for Metastatic Colorectal Cancer Patients Treated with Prior Bevacizumab within 6 Months. | Oncology. |
| Kawai S, Shimoda T, Nakajima T, Terashima M, Omae K, Machida N, Yasui H | Pathological response measured using virtual microscopic slides for gastric cancer patients who underwent neoadjuvant chemotherapy. | World J Gastroenterol. |
| Yasui H, Kawakami T, Kashiwagi H, Mori K, Omae K, Kasai J, Yoshisue K, Kawahira M, Tsushima T, Machida N, Fukutomi A, Yamaguchi K | Pharmacokinetics of S-1 monotherapy in plasma and in tears for gastric cancer patients. | Int J Clin Oncol. |
| Yamazaki K, Doi T, Ikeda M et al. | Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma. | Cancer chemotherapy and pharmacology. |
| Hamauchi S, Yokota T, Mizumachi T, Onozawa Y, Ogawa H, Onoe T, Kamijo T, Iida Y, Nishimura T, Onitsuka T, Yasui H, Homma A. | Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin. | Int J Clin Oncol. |
| Shimada A, Tsushima T, Tsubosa Y, Booka E, Takebayashi K, Niihara M, Isaka M, Ohde Y, Machida N, Onozawa Y, Yasui H, Takeuchi H, Kitagawa Y. | Validity of Surgical Resection for Lymph Node or Pulmonary Recurrence of Esophageal Cancer After Definitive Treatment. | World J Surg. |
| Masuishi T, Taniguchi H, Kawakami T, Kawamoto Y, Kadowaki S, Onozawa Y, Muranaka T, Tajika M, Yasui H, Nakatsumi H, Yuki S, Muro K, Omae K, Komatsu Y, Yamazaki K. | Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer. | ESMO Open. |
| Fujii S, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shinozaki E, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K. | Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing | Biomed Rep |
| Hamaguchi T, Denda T, Kudo T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T, Itabashi M, Oki E, Sasaki T, Chiron M, Yoshino T. | Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer | Cancer Sci |
| Denda T, Sakai D, Hamaguchi T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T, Itabashi M, Oki E, Sasaki T, Sunaga Y, Ziti-Ljajic S, Brillac C, Yoshino T. | Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer | Cancer Sci |
| Fujita Y, Taguri M, Yamazaki K, Tsurutani J, Sakai K, Tsushima T, Nagase M, Tamagawa H, Ueda S, Tamura T, Tsuji Y, Murata K, Taira K, Denda T, Moriwaki T, Funai S, Nakajima TE, Muro K, Tsuji A, Yoshida M, Suyama K, Kurimoto T, Sugimoto N, Baba E, Seki N, Sato M, Shimura T, Boku N, Hyodo I, Yamanaka T, Nishio K. | aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer | Oncologist |
| Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, Azuma M, Sakamoto T, Shitara K, Tamura T, Chin K, Hata H, Nakamori M, Hara H, Yasui H, Katayama H, Fukuda H, Yoshikawa T, Sasako M, Terashima M. | Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial | Lancet Gastroenterol Hepatol |
| Doi T, Aramaki T, Yasui H, Muro K, Ikeda M, Okusaka T, Inaba Y, Nakai K, Ikezawa H, Nakajima R. | A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors | Invest New Drugs |
| Arai H, Iwasa S, Boku N, Kawahira M, Yasui H, Masuishi T, Muro K, Minashi K, Hironaka S, Fukuda N, Takahari D, Nakajima TE. | Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study | BMC Cancer |
| Nishina T, Azuma M, Nishikawa K, Gotoh M, Bando H, Sugimoto N, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Mitome T, Kageyama H, Hyodo I. | Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin | Gastric Cancer |
| Yamada Y, Koizumi W, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Hyodo I. | Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer | Cancer Sci |
| Fukuda H, Yamashita A, Imai T, Tsumaki H, Nagata N, Ishikawa H, Niihara M, Tsubosa Y, Onozawa Y. | Preventive Effect of Nutrition Support on Peroneal Neuropathy in Cancer Patients | Front Nutr |
| Matsuzuka T, Kiyota N, Mizusawa J, Akimoto T, Fujii M, Hasegawa Y, Iwae S, Monden N, Matsuura K, Onozawa Y, Hayashi R, Tahara M; Japan Clinical Oncology Group(JCOG) Head and Neck Cancer Study Group. | Clinical impact of cachexia in unresectable locally advanced head and neck cancer: supplementary analysis of a phase II trial (JCOG0706-S2) | Jpn J Clin Oncol |
| Imamura Y, Kiyota N, Ogawa G, Akimoto T, Fujii M, Hanai N, Iwae S, Monden N, Matsuura K, Onozawa Y, Hayashi R, Tahara M; Japan Clinical Oncology Group (JCOG) Head and Neck Cancer Study Group. | Nutritional support dependence after curative chemoradiotherapy in head and neck cancer: supplementary analysis of a phase II trial (JCOG0706S1) | Jpn J Clin Oncol |
| Hayashi H, Kurata T, Takiguchi Y, Arai M, Takeda K, Akiyoshi K, Matsumoto K, Onoe T, Mukai H, Matsubara N, Minami H, Toyoda M, Onozawa Y, Ono A, Fujita Y, Sakai K, Koh Y, Takeuchi A, Ohashi Y, Nishio K, Nakagawa K. | Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site | J Clin Oncol |
| Head and Neck Cancer Study Group (HNCSG); Monden N, Asakage T, Kiyota N, Homma A, Matsuura K, Hanai N, Kodaira T, Zenda S, Fujii H, Tahara M, Yokota T, Akimoto T, Iwae S, Onitsuka T, Ogawa T, Okano S, Takahashi S, Shimizu Y, Yonezawa K, Hayashi R. | A review of head and neck cancer staging system in the TNM classification of malignant tumors (eighth edition) | Jpn J Clin Oncol |
| Yokota T. | [The Immune Checkpoints Inhibitors for Head and Neck Cancer] | Gan To Kagaku Ryoho |
| Burtness B, Haddad R, Dinis J, Trigo J, Yokota T, de Souza Viana L, Romanov I, Vermorken J, Bourhis J, Tahara M, Martins Segalla JG, Psyrri A, Vasilevskaya I, Nangia CS, Chaves-Conde M, Kiyota N, Homma A, Holeckova P, Del Campo JM, Asarawala N, Nicolau UR, Rauch D, Even C, Wang B, Gibson N, Ehrnrooth E, Harrington K, Cohen EEW; LUX-Head & Neck 2 investigators. | Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial | JAMA Oncol |
| Kobayashi S, Ueno M, Omae K, Kuramochi H, Terao M, Mizuno N, Ozaka M, Ueno H, Uesugi K, Kobayashi N, Kobayashi M, Todaka A, Fukutomi A. | Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer | Oncotarget |
| Matsumoto I, Kamei K, Omae K, Suzuki S, Matsuoka H, Mizuno N, Ozaka M, Ueno H, Kobayashi S, Uesugi K, Kobayashi M, Todaka A, Fukutomi A. | FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan | Pancreatology |
| Doi T, Muro K, Ishii H, Kato T, Tsushima T, Takenoyama M, Oizumi S, Gemmoto K, Suna H, Enokitani K, Kawakami T, Nishikawa H, Yamamoto N. | A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors | Clin Cancer Res |
和文論文
| 著者 | タイトル | ジャーナル | |
| 安井博史、西村誠一郎、渡邊純一郎 | 静がんメソッド 乳癌編 第2版 | 日本医事新報社 | |
| 横田 知哉 | Quality of Survivalを考慮した頭頸部癌支持療法 放射線皮膚炎に対するステロイド外用薬の有効性を検証するランダム化第3相比較試験 | 頭頸部癌 | (1349-5747)45巻3号 Page268-271 |
| 井上 博登、山崎 健太郎 | 【これだけは押さえたい!-大腸癌取扱い規約・治療ガイドライン-改訂のポイント】大腸癌治療ガイドライン2019 外科医が知っておくべき進行再発切除不能癌の治療戦略 腫瘍占居部位とマーカー | 臨床外科 | (0386-9857)74巻8号 Page978-982 |
| 白数 洋充、山﨑 健太郎 | 【消化管がん】Tumor agnostic MSI-High固形がんに対する国内外のガイドライン | 腫瘍内科 | (1881-6568)23巻6号 Page554-560 |
| 對馬 隆浩、町田 望 | 研修医からの質問 Q&A 複合型腺神経内分泌癌(MANEC)への治療として、神経内分泌細胞癌に対する化学療法の他、大腸がんの治療レジメンを用いることも可能でしょうか?最適な治療法は何になるのでしょうか? | 臨床腫瘍プラクティス | (1880-3083)15巻1号 Page64 |
| 横田 知哉 | 【進行頭頸部癌治療の最前線】頭頸部癌における免疫チェックポイント阻害剤開発の最前線 | 癌と化学療法 | (0385-0684)46巻1号 Page21-27 |